CervoMed Sets Phase 3 Dosing Regimen for Lewy Body Dementia Trial
Event summary
- CervoMed selected 50mg TID dosing regimen for Phase 3 trial in dementia with Lewy bodies (DLB) using a stable crystal form of neflamapimod.
- Phase 1 study confirmed pharmacokinetic profile of the new formulation overlaps with the clinically active DP Batch B from the Phase 2b RewinD-LB trial.
- The dose increase from 40mg to 50mg aims to achieve plasma drug concentrations observed with the effective drug product batch.
- CervoMed developed a controlled manufacturing process to address prior issues with drug substance polymorphs and bioavailability.
The big picture
CervoMed's decision to adjust the dosing regimen for its Phase 3 trial in DLB reflects a strategic effort to address prior manufacturing challenges and ensure therapeutic efficacy. The move aligns with broader industry trends in neurodegenerative disease treatment, where precise dosing and formulation stability are critical for clinical success. The company's focus on patients without Alzheimer’s disease co-pathology also highlights a targeted approach to a specific patient population within the broader dementia landscape.
What we're watching
- Clinical Efficacy
- Whether the increased dose of 50mg TID will replicate the positive clinical outcomes observed in the Phase 2b RewinD-LB trial.
- Manufacturing Stability
- The effectiveness of the new controlled manufacturing process in maintaining the stability and bioavailability of neflamapimod.
- Funding and Timing
- The pace at which CervoMed can secure sufficient funding and initiate the planned Phase 3 trial in the second half of 2026.
Related topics